ChemoCentryx-Vifor Pharma Kidney Health Alliance
In 2016, we established a broad Kidney Health Alliance through two significant license agreements with Vifor Pharma to commercialize avacopan and CCX140 in certain licensed territories outside the U.S. In aggregate, the agreements provide the following:
- May 2016 Avacopan Alliance: Vifor Pharma has rights to commercialize avacopan (formerly CCX168) for orphan and rare renal diseases in Europe and certain other territories. ChemoCentryx retains commercial rights in the U.S. and Asia (except South Korea) and responsibility for worldwide development of avacopan
- December 2016 CCX140 Alliance: Vifor Pharma has rights to commercialize CCX140 for renal diseases and the alliance will initially focus on rare kidney diseases. ChemoCentryx retains development control and commercial rights for CCX140 for rare renal disease including FSGS in the U.S. and China, while Vifor Pharma has commercialization rights in the rest of the world
- Vifor Pharma has a future option to solely develop and commercialize CCX140 in chronic kidney disease while ChemoCentryx would retain co-promotion rights in the U.S.
- $135 million in aggregate upfront cash commitments; $1.2 billion in potential development, regulatory and sales milestone payments and royalties in the teens to mid-twenties on net sales in the Vifor Pharma territories
Vifor Pharma, together with its nephrology partner company Vifor Fresenius Medical Care Renal Pharma, is a world leader in delivering quality care for patients with kidney disease. Vifor Pharma’s renal medicines specialization, including access to a vast patient database and nephrology-focused commercial expertise, will be a valuable resource for the development and potential commercialization of avacopan and CCX140. We believe that the establishment of this Kidney Health Alliance with Vifor Pharma further validates the ChemoCentryx approach to blocking chemoattractant receptors such as C5aR and CCR2 in the inflammatory processes in several rare renal diseases.